Page 272 of 440: studies 2,711 to 2,720 of 4,392, newest first. Back to the psilocybin overview
Expert Review of Clinical Pharmacology December 17, 2017 Alexander M. Sherwood, Thomas E Prisinzano
Disrupted mental health affects up to one in three individuals globally and is an unmet medical challenge contributing to individual suffering as well as significant societal and economic burden [1...
Psychiatric News November 30, 2017 Richard Karel
3,4-methylenedioxymethamphetamine (MDMA) holds promise to once again become a therapeutic tool. After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential "breakthrough therapy" for treatment of posttraumatic stress disorder (PTSD). The complex...
Frontiers in Psychiatry November 20, 2017 Laura Orsolini, Gabriele Duccio Papanti, Domenico de Berardis et al. 99 citations
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel...
Frontiers in Pharmacology November 8, 2017 Rainer Kraehenmann, Dan Pokorný, Helena Aicher et al. 115 citations
Rationale: Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is...
Journal of Psychopharmacology October 17, 2017 Peter S. Hendricks, Michael S Crawford, Karen L. Cropsey et al. 91 citations
Criminal behavior exacts a large toll on society and is resistant to intervention. Some evidence suggests classic psychedelics may inhibit criminal behavior, but the extent of these effects has not been comprehensively explored. In this study, we tested the relationships of classic psychedelic use and psilocybin use per se with criminal behavior among over 480,000 United States adult...
TIPS - Trends in Pharmacological Sciences September 22, 2017 Evan J. Kyzar, Charles D. Nichols, Raul R. Gainetdinov et al. 155 citations
Psychedelic drugs, such as lysergic acid diethylamide (LSD), mescaline, and psilocybin, exert profound effects on brain and behavior. After decades of difficulties in studying these compounds, psychedelics are again being tested as potential treatments for intractable biomedical disorders. Preclinical research of psychedelics complements human neuroimaging studies and pilot clinical trials,...
Harm Reduction Journal September 4, 2017 Martin Andersson, Mari Persson, Anette Kjellgren 93 citations
BACKGROUND: Treatment resistant cluster headache and migraine patients are exploring alternative treatments online. The aim of this study was to improve comprehension regarding the use of non-established or alternative pharmacological treatments used by sufferers of cluster headaches and migraines. METHODS: A qualitative thematic analysis of the users' own accounts presented in online forum...
Drug Testing and Analysis August 29, 2017 Torsten Passie, Udo Benzenhöfer 43 citations
Abstract This article describes the context in which 3,4‐methylenedioxyamphetamine (MDA), 3,4‐methylenedioxymethamphetamine (MDMA) and other mescaline‐like compounds were explored as hallucinogens for military and intelligence purposes from the 1940s to the 1960s. Germans first tested mescaline as a “truth drug” in a military context. In the 1940s, the United States military started testing...
Journal of Psychedelic Studies August 29, 2017 Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre et al. 39 citations
Objective This report documents the phenomenology of the subjective experiences of 22 patients with substance-related disorders who were involved in a treatment combining cognitive–behavioral therapy and hospital sessions with ibogaine in Brazil. Methods Participants underwent a one-to-one semi-structured interview exploring the subjective effects of ibogaine. We employed interpretative...
Clinical Pharmacology & Therapeutics August 24, 2017 Edward M. Sellers, Deborah B. Leiderman 27 citations
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.